Metro Infectious Disease Libertyville, IL - 60048

Metro Infectious Disease is categorized under Medical Centers in Libertyville, IL and active since 2007.

Metro Infectious Disease was established in 2007, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Medical Centers business, which does work in the B2C market, and is classified as a Medical Centers, under code number 6214930 by the NAICS.

If you are seeking more information, feel free to contact John Matseshe at the company’s single location by writing to 890 Garfield Avenue # 210, Libertyville, Illinois IL 60048 or by phoning (847) 816-6538. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Metro Infectious Disease
Contact Person: John Matseshe
Address: 890 Garfield Avenue # 210, Libertyville, Illinois 60048
Phone Number: (847) 816-6538
Website Address: metroinfusioncenter.com
Annual Revenue (USD): $100.000 to $499.999
Founded: 2007
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Medical Centers
SIC Code: 8011
NAICS Code: 6214930
Share This Business:

Metro Infectious Disease was started in 2007 to provide professional Medical Centers under the SIC code 8011 and NAICS code 6214930. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.

Feel free to contact John Matseshe for inquiries that concern Metro Infectious Disease by calling the company number (847) 816-6538, as your correspondence is most welcome. Additionally, the physical location of the single location of Metro Infectious Disease can be found at the coordinates 42.26998,-87.95707 as well as the street address 890 Garfield Avenue # 210 in Libertyville, Illinois 60048.

For its online presence, you may visit Metro Infectious Disease’s website at metroinfusioncenter.com and engage with its social media outlets through on Twitter and on Facebook.